Tags : Recovery

Eli Lilly and Incyte’s Olumiant + Gilead’s Veklury Reduce Time

Shots: Eli Lilly and Incyte report the initial result of NIAID sponsored ACTT-2 study assessing the efficacy and safety of Olumiant (baricitinib, 4mg) + Veklury (remdesivir) vs Veklury as monothx. in hospitalized patients with COVID-19 The study met its EPs i.e. it demonstrated 1day reduction in median recovery time for the overall patient population and […]Read More